source
- Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challengesAcquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
- Biogen's low-dose tau drug shows greater slowing of Alzheimer’s progression after two yearsBiogen reported new data on its experimental tau-reducing therapy diranersen, showing that the lowest dose continued to slow Alzheimer’s disease progression after nearly two years of treatment. Th…